drugset
drugset / Trial / NCT05651152

A Study to Investigate The Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of JZP441 in Sleep-deprived Healthy Participants

NCT05651152 ↗

Phase 1 Completed 105 enrolled Jazz Pharmaceuticals
RandomizedParallel-groupDouble-blindTreatment

Summary

This Phase 1, double-blind, randomized, placebo-controlled study will characterize the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of ascending nighttime doses of JZP441 in sleep-deprived healthy participants.

Timeline

Start
2022-11-28
Primary completion
2023-11-15
Completion
2023-11-15

Drugs

EvaluationDrugModalityDoseRoute
Subject JZP441 Unknown — Oral

Indications

No indication recorded.